MedDataX Logo

A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder

NCT ID: NCT01103362

Last Updated: 2014-05-12

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

596 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To generate additional long-term safety and efficacy data on flibanserin in premenopausal women and establish long-term safety and tolerability of flibanserin in naturally postmenopausal women with Hypoactive Sexual Desire Disorder who have completed a prior clinical trial of flibanserin (Trial 511.130, 511.147, or 511.156).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT00996372

Sexual Dysfunctions, Psychological
COMPLETED PHASE3

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

NCT01057901

Sexual Dysfunctions, Psychological
TERMINATED PHASE3

24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00360529

Sexual Dysfunctions, Psychological
COMPLETED PHASE3

Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder

NCT00601367

Sexual Dysfunctions, Psychological
COMPLETED PHASE3

Flibanserin Versus Placebo in Premenopausal Women With HSDD

NCT00491829

Sexual Dysfunctions, Psychological
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sexual Dysfunctions, Psychological

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

flibanserin 100mg

flibanserin 100mg po qd

Group Type EXPERIMENTAL

flibanserin

Intervention Type DRUG

all patients will receive open-label flibanserin 100mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

flibanserin

all patients will receive open-label flibanserin 100mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women with primary diagnosis of Hypoactive Sexual Desire Disorder (HSDD) who completed a prior trial of flibanserin. Such completion requires compliance with trial medication and the trial visit schedule including any post-treatment visits required in that clinical trial. Early discontinuation for any reason disqualifies the patient from entry into this trial. Patients must enroll in this study within 7 days after completing the final visit of the parent trial.
2. The premenopausal patient must use a medically acceptable method of contraception for at least two months before baseline and continue to use medically acceptable method of contraception during the trial.
3. Postmenopausal patients must be a naturally postmenopausal woman of any age with at least one ovary. Natural menopause is defined as greater than 12 months of spontaneous amenorrhea.
4. In the investigator's opinion, patients must be willing to adhere to trial requirements as well as to be able to perform them.
5. Patients must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements. Patients must have sufficient understanding to communicate effectively with the investigator, and be willing to discuss sexual functioning with study staff.

Exclusion Criteria

1. Patients with history of Major Depressive Disorder (MDD) within six months prior to the Screen Visit, or a score of greater than or equal to 14 on the Beck Depression Inventory II (BDI-II), or a history of suicidal behavior or suicidal ideation according to the Columbia-Suicide Severity Rating Scale (C-SSRS®). If a psychiatrist or psychologist, using clinical judgment, believes a patient who scored between 14 and 19 on the BDI®-II is not depressed, the patient may be entered into the trial. NOTE: If a patient reports positive response to BDI®-II Question 9 and/or a Yes response to either C-SSRS® Suicide Ideation section Question 1 and/or 2 and/or any question in the Suicide Behavior section, please refer to Section 5.2.5 for immediate actions required.
2. At the Screen Visit, serum alanine aminotransferase, serum aspartate aminotransferase, alkaline phosphatase, or total bilirubin greater than or equal to three times upper limit of normal; blood urea nitrogen greater than or equal to 30 mg/deciliter (dL), plasma creatinine greater than or equal to 2 mg/dL, hemoglobin \<9.5 grams/dL, leukopenia (\<2.5 x 103/microliter \[µL\]), neutropenia (\<1.5 x 103/µL), lymphopenia (\<0.8 x 103/µL), thrombocytopenia (\<100 x 103/µL) or thrombocytosis (\>500 x 103/µL); or random glucose \> upper limit of normal.
3. Patients with newly developed, self-reported symptoms after the End of Treatment parent trial visit and at this trial Screen Visit of pelvic inflammatory disease, urinary tract or vaginal infection / vaginitis, cervicitis, interstitial cystitis, vulvodynia, or significant vaginal atrophy.
4. Patients with history of any cancer within the last ten years, other than non-invasive, previously resected basal cell carcinoma of the skin.
5. Patients whose sexual function was affected by hysterectomy, oophorectomy, or any other pelvic or vaginal surgery.
6. Patients who are pregnant (by urine pregnancy test at the Screen Visit) or have been pregnant within the month prior to the Screen Visit or who are breast-feeding or have breast-fed within the last six months prior to the Baseline Visit.
7. Patients receiving medication excluded in their prior safety and efficacy trial of flibanserin causing sexual dysfunction or safety-relevant interactions (i.e., antidepressants, anxiolytics, antipsychotics, anticonvulsants, anticoagulants).
8. Patients with clinically relevant conditions which might interfere with their ability to participate in the trial.
9. Participation in a trial of an investigational medication other than flibanserin within one month prior to the Screen Visit.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sprout Pharmaceuticals, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sprout Pharmaceuticals

Role: STUDY_CHAIR

Sprout Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

511.133.01074 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

511.133.01141 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Site Status

511.133.01046 Boehringer Ingelheim Investigational Site

Huntsville, Alabama, United States

Site Status

511.133.01042 Boehringer Ingelheim Investigational Site

Mobile, Alabama, United States

Site Status

511.133.01025 Boehringer Ingelheim Investigational Site

Phoenix, Arizona, United States

Site Status

511.133.01073 Boehringer Ingelheim Investigational Site

Phoenix, Arizona, United States

Site Status

511.133.01127 Boehringer Ingelheim Investigational Site

Tuscon, Arizona, United States

Site Status

511.133.01030 Boehringer Ingelheim Investigational Site

Encinitas, California, United States

Site Status

511.133.01028 Boehringer Ingelheim Investigational Site

Fair Oaks, California, United States

Site Status

511.133.01037 Boehringer Ingelheim Investigational Site

Irvine, California, United States

Site Status

511.133.01136 Boehringer Ingelheim Investigational Site

La Mesa, California, United States

Site Status

511.133.01128 Boehringer Ingelheim Investigational Site

Newport Beach, California, United States

Site Status

511.133.01115 Boehringer Ingelheim Investigational Site

Oceanside, California, United States

Site Status

511.133.01022 Boehringer Ingelheim Investigational Site

Sacremento, California, United States

Site Status

511.133.01035 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Site Status

511.133.01052 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Site Status

511.133.01099 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Site Status

511.133.01016 Boehringer Ingelheim Investigational Site

Tarzana, California, United States

Site Status

511.133.01021 Boehringer Ingelheim Investigational Site

Vista, California, United States

Site Status

511.133.01051 Boehringer Ingelheim Investigational Site

Westlake Village, California, United States

Site Status

511.133.01071 Boehringer Ingelheim Investigational Site

Denver, Colorado, United States

Site Status

511.133.01053 Boehringer Ingelheim Investigational Site

Farmington, Connecticut, United States

Site Status

511.133.01015 Boehringer Ingelheim Investigational Site

Groton, Connecticut, United States

Site Status

511.133.01139 Boehringer Ingelheim Investigational Site

New London, Connecticut, United States

Site Status

511.133.01064 Boehringer Ingelheim Investigational Site

Newark, Delaware, United States

Site Status

511.133.01062 Boehringer Ingelheim Investigational Site

Washington D.C., District of Columbia, United States

Site Status

511.133.01003 Boehringer Ingelheim Investigational Site

Boynton Beach, Florida, United States

Site Status

511.133.01056 Boehringer Ingelheim Investigational Site

Clearwater, Florida, United States

Site Status

511.133.01132 Boehringer Ingelheim Investigational Site

Coral Gables, Florida, United States

Site Status

511.133.01065 Boehringer Ingelheim Investigational Site

Daytona Beach, Florida, United States

Site Status

511.133.01020 Boehringer Ingelheim Investigational Site

Miami, Florida, United States

Site Status

511.133.01024 Boehringer Ingelheim Investigational Site

Miami, Florida, United States

Site Status

511.133.01043 Boehringer Ingelheim Investigational Site

Orlando, Florida, United States

Site Status

511.133.01070 Boehringer Ingelheim Investigational Site

Palm Harbor, Florida, United States

Site Status

511.133.01019 Boehringer Ingelheim Investigational Site

St. Petersburg, Florida, United States

Site Status

511.133.01061 Boehringer Ingelheim Investigational Site

Tampa, Florida, United States

Site Status

511.133.01066 Boehringer Ingelheim Investigational Site

Tampa, Florida, United States

Site Status

511.133.01001 Boehringer Ingelheim Investigational Site

West Palm Beach, Florida, United States

Site Status

511.133.01002 Boehringer Ingelheim Investigational Site

West Palm Beach, Florida, United States

Site Status

511.133.01009 Boehringer Ingelheim Investigational Site

Atlanta, Georgia, United States

Site Status

511.133.01023 Boehringer Ingelheim Investigational Site

Atlanta, Georgia, United States

Site Status

511.133.01082 Boehringer Ingelheim Investigational Site

Marietta, Georgia, United States

Site Status

511.133.01008 Boehringer Ingelheim Investigational Site

Sandy Springs, Georgia, United States

Site Status

511.133.01044 Boehringer Ingelheim Investigational Site

Chicago, Illinois, United States

Site Status

511.133.01034 Boehringer Ingelheim Investigational Site

Indianapolis, Indiana, United States

Site Status

511.133.01100 Boehringer Ingelheim Investigational Site

Wichita, Kansas, United States

Site Status

511.133.01067 Boehringer Ingelheim Investigational Site

Lafayette, Louisiana, United States

Site Status

511.133.01013 Boehringer Ingelheim Investigational Site

Baltimore, Maryland, United States

Site Status

511.133.01031 Boehringer Ingelheim Investigational Site

Bingham Farms, Michigan, United States

Site Status

511.133.01006 Boehringer Ingelheim Investigational Site

St Louis, Missouri, United States

Site Status

511.133.01014 Boehringer Ingelheim Investigational Site

Billings, Montana, United States

Site Status

511.133.01060 Boehringer Ingelheim Investigational Site

Omaha, Nebraska, United States

Site Status

511.133.01057 Boehringer Ingelheim Investigational Site

Las Vegas, Nevada, United States

Site Status

511.133.01039 Boehringer Ingelheim Investigational Site

Moorestown, New Jersey, United States

Site Status

511.133.01017 Boehringer Ingelheim Investigational Site

Endwell, New York, United States

Site Status

511.133.01135 Boehringer Ingelheim Investigational Site

Cary, North Carolina, United States

Site Status

511.133.01047 Boehringer Ingelheim Investigational Site

New Bern, North Carolina, United States

Site Status

511.133.01027 Boehringer Ingelheim Investigational Site

Winston-Salem, North Carolina, United States

Site Status

511.133.01138 Boehringer Ingelheim Investigational Site

Winston-Salem, North Carolina, United States

Site Status

511.133.01119 Boehringer Ingelheim Investigational Site

Fargo, North Dakota, United States

Site Status

511.133.01033 Boehringer Ingelheim Investigational Site

Cincinnati, Ohio, United States

Site Status

511.133.01004 Boehringer Ingelheim Investigational Site

Cleveland, Ohio, United States

Site Status

511.133.01050 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Site Status

511.133.01059 Boehringer Ingelheim Investigational Site

Columbus, Ohio, United States

Site Status

511.133.01058 Boehringer Ingelheim Investigational Site

Dayton, Ohio, United States

Site Status

511.133.01105 Boehringer Ingelheim Investigational Site

Englewood, Ohio, United States

Site Status

511.133.01072 Boehringer Ingelheim Investigational Site

Edmond, Oklahoma, United States

Site Status

511.133.01007 Boehringer Ingelheim Investigational Site

Eugene, Oregon, United States

Site Status

511.133.01055 Boehringer Ingelheim Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

511.133.01068 Boehringer Ingelheim Investigational Site

Mt. Pleasant, South Carolina, United States

Site Status

511.133.01084 Boehringer Ingelheim Investigational Site

Chattanooga, Tennessee, United States

Site Status

511.133.01063 Boehringer Ingelheim Investigational Site

Knoxville, Tennessee, United States

Site Status

511.133.01010 Boehringer Ingelheim Investigational Site

Nashville, Tennessee, United States

Site Status

511.133.01036 Boehringer Ingelheim Investigational Site

Nashville, Tennessee, United States

Site Status

511.133.01018 Boehringer Ingelheim Investigational Site

Corpus Christi, Texas, United States

Site Status

511.133.01032 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

511.133.01011 Boehringer Ingelheim Investigational Site

Katy, Texas, United States

Site Status

511.133.01012 Boehringer Ingelheim Investigational Site

San Antonio, Texas, United States

Site Status

511.133.01026 Boehringer Ingelheim Investigational Site

San Antonio, Texas, United States

Site Status

511.133.01005 Boehringer Ingelheim Investigational Site

Salt Lake City, Utah, United States

Site Status

511.133.01069 Boehringer Ingelheim Investigational Site

Sandy City, Utah, United States

Site Status

511.133.01040 Boehringer Ingelheim Investigational Site

Norfolk, Virginia, United States

Site Status

511.133.01029 Boehringer Ingelheim Investigational Site

Richmond, Virginia, United States

Site Status

511.133.01075 Boehringer Ingelheim Investigational Site

Richmond, Virginia, United States

Site Status

511.133.01049 Boehringer Ingelheim Investigational Site

Virgnia Beach, Virginia, United States

Site Status

511.133.01054 Boehringer Ingelheim Investigational Site

Renton, Washington, United States

Site Status

511.133.01045 Boehringer Ingelheim Investigational Site

Spokane, Washington, United States

Site Status

511.133.01038 Boehringer Ingelheim Investigational Site

Tacoma, Washington, United States

Site Status

511.133.02004 Boehringer Ingelheim Investigational Site

Calgary, Alberta, Canada

Site Status

511.133.02014 Boehringer Ingelheim Investigational Site

Victoria, British Columbia, Canada

Site Status

511.133.02006 Boehringer Ingelheim Investigational Site

Burlington, Ontario, Canada

Site Status

511.133.02005 Boehringer Ingelheim Investigational Site

Ottawa, Ontario, Canada

Site Status

511.133.02016 Boehringer Ingelheim Investigational Site

Toronto, Ontario, Canada

Site Status

511.133.02002 Boehringer Ingelheim Investigational Site

Québec, Quebec, Canada

Site Status

511.133.02003 Boehringer Ingelheim Investigational Site

Saskatoon, Saskatchewan, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Simon JA, Derogatis L, Portman D, Brown L, Yuan J, Kissling R. Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study. J Sex Med. 2018 Mar;15(3):387-395. doi: 10.1016/j.jsxm.2017.12.016.

Reference Type DERIVED
PMID: 29502984 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

511.133

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
NCT00996164 COMPLETED PHASE3
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
NCT01188603 COMPLETED PHASE1
Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women
NCT00277914 COMPLETED PHASE3
Effects of Flibanserin on the Pre- and Post-menopausal Female Brain
NCT02770768 TERMINATED NA
Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems
NCT01743235 COMPLETED PHASE2
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
NCT00613002 COMPLETED PHASE3
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
NCT00612742 COMPLETED PHASE3
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
NCT01382719 COMPLETED PHASE2
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
NCT02338960 COMPLETED PHASE3
Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety
NCT01857596 COMPLETED PHASE1/PHASE2
Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.
NCT00479570 COMPLETED PHASE2
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
NCT00657501 COMPLETED PHASE3
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
NCT00331123 COMPLETED PHASE3
Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder
NCT02101203 COMPLETED PHASE2
Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
NCT00349791 COMPLETED PHASE3
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
NCT00338312 COMPLETED PHASE3
Safety Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women
NCT02215434 COMPLETED PHASE2
Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen
NCT00384046 COMPLETED PHASE3
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity
NCT00729469 COMPLETED PHASE3
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
NCT00482664 COMPLETED PHASE2
Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
NCT00535288 COMPLETED PHASE3
Clinical Trial to Investigate the Effectiveness of a Dietary Supplement in Increasing Libido and Sexual Function in Postmenopausal Women.
NCT03820453 UNKNOWN NA
Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder
NCT06116045 RECRUITING PHASE2
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
NCT00331214 COMPLETED PHASE3
Zestra in Women With Mixed Sexual Dysfunction
NCT00118495 COMPLETED PHASE3